Celecoxib-d3(Synonyms: SC 58635-d3)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Celecoxib-d3 (Synonyms: SC 58635-d3)

Celecoxib-d3 (SC 58635-d3) 是 Celecoxib 的氘代物。Celecoxib 是一种选择性的 COX-2 抑制剂,IC50 为 40 nM。

Celecoxib-d3(Synonyms: SC 58635-d3)

Celecoxib-d3 Chemical Structure

CAS No. : 544686-18-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Celecoxib-d3 (SC 58635-d3) is the deuterium labeled Celecoxib. Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM[1][2].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

384.39

Formula

C17H11D3F3N3O2S

CAS 号

544686-18-2

中文名称

塞来昔布 d3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Penning TD, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem. 1997

    [3]. Liu DB, et al. Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. Acta Pharmacol Sin. 2012 May;33(5):682-90.

    [4]. Suri A, et al. The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer. Oncotarget. 2016 Apr 8.

    [5]. Hou XL, et al. Combination of fasudil and celecoxib promotes the recovery of injured spinal cord in rats better than celecoxib or fasudil alone. Neural Regen Res. 2015 Nov;10(11):1836-40.

    [6]. Liu C, et al. Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux. Sci Rep. 2018 Mar 7;8(1):4108.

    [7]. Pobbati AV, et al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020 Feb 18;10(8):3622-3635.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

SC-236

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

SC-236  纯度: 99.45%

SC-236 是具有口服活性的 COX-2 特异性抑制剂 (对 COX-1 的 IC50 值为 10 nM)和 PPARγ 激动剂。SC-236 可通过 c-Jun 氨基端抑制激活蛋白-1 (AP-1) 活性。SC-236在小鼠模型中通过抑制 ERK 的磷酸化发挥抗炎作用。

SC-236

SC-236 Chemical Structure

CAS No. : 170569-86-5

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥880 In-stock
5 mg ¥800 In-stock
10 mg ¥1200 In-stock
25 mg ¥2500 In-stock
50 mg ¥4500 In-stock
100 mg ¥7500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

SC-236 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Cell Cycle/DNA Damage Compound Library
  • Immunology/Inflammation Compound Library
  • Kinase Inhibitor Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Pyroptosis Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Transcription Factor Targeted Library
  • Anti-Colorectal Cancer Compound Library

生物活性

SC-236 is an orally active COX-2 specific inhibitor (IC50 = 10 nM) and a PPARγ agonist. SC-236 suppresses activator protein-1 (AP-1) through c-Jun NH2-terminal kinase. SC-236 exerts anti-inflammatory effects by suppressing phosphorylation of ERK in a murine model[1][2][3][4][5].

IC50 & Target[5]

COX-2

10 nM (IC50)

COX-1

17.8 μM (IC50)

体外研究
(In Vitro)

SC-236 (15 μM, 30 min) suppresses the side effects of NSAIDs and prevented inflammation in vECs subjected to ALSS[1].
SC-236 significantly induces PPARγ expression in HSCs and acted as a potent PPARγ agonist in a luciferase-reporter trans-activation assay[2].
SC-236 strongly inhibits, in a time- and concentration-dependent manner, macrophage viability[2].
SC-236, either alone or in combination with 15d-PGJ2, induced a marked pro-apoptotic effect in HSCs in culture[2].
SC-236 mediates antitumor effect by modulation of AP-1-signaling pathway[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: vECs.
Concentration: 15 μM
Incubation Time: 30 min.
Result: Showd significant reduction in COX-2 level and increase in IκBα level, thus preventing ALSS-induced NFκB activation and inflammation in vECs.

Western Blot Analysis[2]

Cell Line: COS 7 cells.
Concentration: 3 and 10 μM.
Incubation Time: 18 h (combined with 15d-PGJ2).
Result: Acted in a concentration-dependent manner as a PPARγ agonist.

体内研究
(In Vivo)

SC-236 (6 mg/kg, gavage) exhibits anti-fibrotic properties in CCl4- treated animals[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Seventy-six male adult Wistar rats weighing 200-220 g (CCl4-treated)[2].
Dosage: 6 mg/kg.
Administration: Orally, 3 times per week.
Result: A marked induction of COX-2 protein expression was detected by immunohistochemistry in the liver of CCl4-treated rats.
Significantly reduced the degree of liver fibrosis.
Dramatically suppressed α-SMA expression in CCl4-treated rats.

分子量

401.79

Formula

C16H11ClF3N3O2S

CAS 号

170569-86-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (248.89 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.4889 mL 12.4443 mL 24.8886 mL
5 mM 0.4978 mL 2.4889 mL 4.9777 mL
10 mM 0.2489 mL 1.2444 mL 2.4889 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: 2.5 mg/mL (6.22 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (6.22 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (6.22 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.22 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (6.22 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.22 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Shao-Yu Fang, et al. Reduction in MicroRNA-4488 Expression Induces NFκB Translocation in Venous Endothelial Cells Under Arterial Flow. Cardiovasc Drugs Ther. 2020 Sep 9.

    [2]. Anna Planagumà, et al. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. FASEB J. 2005 Jul;19(9):1120-2.

    [3]. Benjamin Chun-Yu Wong, et al. Cyclooxygenase-2 inhibitor (SC-236) suppresses activator protein-1 through c-Jun NH2-terminal kinase. Gastroenterology. 2004 Jan;126(1):136-47.

    [4]. Su-Jin Kim, et al. The COX-2 inhibitor SC-236 exerts anti-inflammatory effects by suppressing phosphorylation of ERK in a murine model. Life Sci. 2007 Aug 23;81(11):863-72.

    [5]. T D Penning, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem. 1997 Apr 25;40(9):1347-65.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Parecoxib(Synonyms: 帕瑞昔布; SC 69124)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Parecoxib (Synonyms: 帕瑞昔布; SC 69124) 纯度: 98.34%

Parecoxib (SC 69124) 是一种选择性强、口服活性强的 COX-2 抑制剂,Valdecoxib (HY-15762) 的前药。Parecoxib Sodium 是一种非甾体抗炎试剂 (NSAID),可抑制前列腺素(PG) 的合成。动物实验中,Parecoxib Sodium 可用于缓解术后急性疼痛和骨关节炎、类风湿关节炎等慢性炎症症状。

Parecoxib(Synonyms: 帕瑞昔布; SC 69124)

Parecoxib Chemical Structure

CAS No. : 198470-84-7

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥770 In-stock
25 mg ¥700 In-stock
50 mg ¥1200 In-stock
100 mg ¥2000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Parecoxib 相关产品

相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Anti-COVID-19 Compound Library
  • NMPA-Approved Drug Library
  • Pyroptosis Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Anti-Pancreatic Cancer Compound Library
  • Rare Diseases Drug Library
  • Anti-Colorectal Cancer Compound Library

生物活性

Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the prodrug of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo[1][2].

IC50 & Target[1]

COX-2

 

体外研究
(In Vitro)

Parecoxib (0-200 μM; 24-48 hours) inhibits the cell proliferation of GBM cells in a dose-dependent manner in GBM cells[4].
Parecoxib (200 μM; 24-48 hours) results in a decreasee migratory ability of U343 cells than PBS-treated group[4].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[4]

Cell Line: GBM cells: U251 and U343 cells
Concentration: 0 μM, 20 μM, 50 μM, 100 μM and 200 μM
Incubation Time: 24-48 hours
Result: Resulted in a slower BrdU incorporation rate of GBM cells including U251 and U343 cells.

体内研究
(In Vivo)

Parecoxib (intraperitoneal injection; 2.5, 5.0 or 10 mg/kg; once a day; 21 days) does not affect locomotor activity in the elevated plus-maze test, and Parecoxib at 5 and 10 mg/kg shows higher levels of percentage of time spent in the open arms[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Naive adult male ICR mice, 15 weeks old and weighing 25-35 g[3]
Dosage: 2.5, 5.0 or 10 mg/kg
Administration: Intraperitoneal injection; 2.5, 5.0 or 10 mg/kg; once a day; 21 days
Result: Exerted an anxiolytic-like effect in the elevated plus-maze test

Clinical Trial

分子量

370.42

Formula

C19H18N2O4S

CAS 号

198470-84-7

中文名称

帕瑞昔布;帕瑞考昔

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 50 mg/mL (134.98 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.6996 mL 13.4982 mL 26.9964 mL
5 mM 0.5399 mL 2.6996 mL 5.3993 mL
10 mM 0.2700 mL 1.3498 mL 2.6996 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (6.75 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.75 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (6.75 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.75 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Jun Tang, et al. Effect of parecoxib, a novel intravenous cyclooxygenase type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology

    [2]. J L Mateos, et al.[Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review]. Drugs Today (Barc). 2010 Feb;46 Suppl A:1-25.

    [3]. Bo Wang, et al. Chronic administration of parecoxib exerts anxiolytic-like and memory enhancing effects and modulates synaptophysin expression in mice. BMC Anesthesiol. 2017 Nov 13;17(1):152.

    [4]. Lin-Yong Li, et al. Parecoxib inhibits glioblastoma cell proliferation, migration and invasion by upregulating miRNA-29c. Biol Open. 2017 Mar 15;6(3):311-316.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Domatinostat tosylate(Synonyms: 4SC-202)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Domatinostat tosylate (Synonyms: 4SC-202) 纯度: 99.66%

Domatinostat tosylate (4SC-202) 是一种 I 型 HDAC 抑制剂,能够抑制 HDAC1,HDAC2,和 HDAC3 的活性,IC50 值分别为 1.20 μM,1.12 μM 和 0.57 μM;同时能够抑制组蛋白赖氨酸特异性脱甲基酶1 (Lysine specific demethylase 1) 的活性。

Domatinostat tosylate(Synonyms: 4SC-202)

Domatinostat tosylate Chemical Structure

CAS No. : 1186222-89-8

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥1636 In-stock
2 mg ¥800 In-stock
5 mg ¥1200 In-stock
10 mg ¥1800 In-stock
50 mg ¥5100 In-stock
100 mg ¥8150 询价
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Domatinostat tosylate 相关产品

相关化合物库:

  • Covalent Screening Library Plus
  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Cell Cycle/DNA Damage Compound Library
  • Epigenetics Compound Library
  • Histone Modification Research Compound Library
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Covalent Screening Library
  • Reprogramming Compound Library
  • Oxygen Sensing Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Liver Cancer Compound Library

生物活性

Domatinostat tosylate (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against Lysine specific demethylase 1 (LSD1).

IC50 & Target[4]

HDAC-3

0.57 μM (IC50)

HDAC-2

1.12 μM (IC50)

HDAC-1

1.2 μM (IC50)

HDAC-11

9.7 μM (IC50)

HDAC-5

11.3 μM (IC50)

HDAC-10

21 μM (IC50)

HDAC-9

50 μM (IC50)

体外研究
(In Vitro)

Domatinostat tosylate significantly reduces proliferation of all epithelial and mesenchymal UC cell lines (IC50 0.15-0.51 μM), inhibits clonogenic growth and induces caspase activity[1]. Domatinostat tosylate provokes apoptosis activation in CRC cells, while caspase inhibitors (z-VAD-CHO and z-DVED-CHO) significantly alleviate Domatinostat tosylate-exerted cytotoxicity in CRC cells. Meanwhile, Domatinostat tosylate induces dramatic G2-M arrest in CRC cells. Further studies show that AKT activation might be an important resistance factor of Domatinostat tosylate. Domatinostat tosylate-induced cytotoxicity is dramatically potentiated with serum starvation, AKT inhibition (by perifosine or MK-2206), or AKT1-shRNA knockdown in CRC cells. On the other hand, exogenous expression of constitutively active AKT1 (CA-AKT1) decreases the sensitivity by Domatinostat tosylate in HT-29 cells. Notably, Domatinostat tosylate, at a low concentration, enhances oxaliplatin-induced in vitro anti-CRC activity[2]. Domatinostat tosylate treatment induces potent cytotoxic and proliferation-inhibitory activities against established HCC cell lines (HepG2, HepB3, SMMC-7721) and patient-derived primary HCC cells. Domatinostat tosylate induces apoptosis signal-regulating kinase 1 (ASK1) activation, causing it translocation to mitochondria and physical association with Cyp-D[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Oral gavage of Domatinostat tosylate inhibits HT-29 xenograft growth in nude mice, and when combined with oxaliplatin, its activity is further strengthened[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

619.71

Formula

C30H29N5O6S2

CAS 号

1186222-89-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

DMSO : ≥ 51 mg/mL (82.30 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.6137 mL 8.0683 mL 16.1366 mL
5 mM 0.3227 mL 1.6137 mL 3.2273 mL
10 mM 0.1614 mL 0.8068 mL 1.6137 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (4.03 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.03 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (4.03 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.03 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Pinkerneil M, et al. Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines. Target Oncol. 2016 Dec;11(6):783-798.

    [2]. S.W.Henning, et al. Preclinical characterization of 4SC-202, a noval isotype specific HDAC inhibitor.

    [3]. Zhijun H, et al. Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells. Tumour Biol. 2016 Aug;37(8):10257-67.

    [4]. Fu M, et al. 4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2016 Mar 4;471(2):267-73

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

SC-Val-Cit-PAB

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

SC-Val-Cit-PAB 

SC-Val-Cit-PAB 是抗体偶联药物 (ADCs) 的常用一种蛋白可降解 (cleavable) 的 ADC linker。

SC-Val-Cit-PAB

SC-Val-Cit-PAB Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

SC-Val-Cit-PAB is a cleavable ADC linker for antibody-drug conjugates (ADCs).

IC50 & Target

Cleavable

 

分子量

604.65

Formula

C28H40N6O9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Parecoxib Sodium(Synonyms: 帕瑞昔布钠; SC 69124A)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Parecoxib Sodium (Synonyms: 帕瑞昔布钠; SC 69124A) 纯度: 99.97%

Parecoxib Sodium (SC 69124A) 是一种选择性强、口服活性强的 COX-2 抑制剂,Valdecoxib (HY-15762) 的前药。Parecoxib Sodium 是一种非甾体抗炎试剂 (NSAID),可抑制前列腺素(PG) 的合成。动物实验中,Parecoxib Sodium 可用于缓解术后急性疼痛和骨关节炎、类风湿关节炎等慢性炎症症状。

Parecoxib Sodium(Synonyms: 帕瑞昔布钠; SC 69124A)

Parecoxib Sodium Chemical Structure

CAS No. : 198470-85-8

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥770 In-stock
25 mg ¥700 In-stock
50 mg ¥1200 In-stock
100 mg ¥2000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Parecoxib Sodium 相关产品

相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Anti-COVID-19 Compound Library
  • NMPA-Approved Drug Library
  • Pyroptosis Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Anti-Pancreatic Cancer Compound Library
  • Rare Diseases Drug Library
  • Anti-Colorectal Cancer Compound Library

生物活性

Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the prodrug of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo[1][2].

IC50 & Target[1]

COX-2

 

体外研究
(In Vitro)

Parecoxib Sodium (0-200 μM; 24-48 hours) inhibits the cell proliferation of GBM cells in a dose-dependent manner in GBM cells[4].
Parecoxib Sodium (200 μM; 24-48 hours) results in a decreased migratory ability of U343 cells than PBS-treated group[4].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[4]

Cell Line: GBM cells: U251 and U343 cells
Concentration: 0 μM, 20 μM, 50 μM, 100 μM and 200 μM
Incubation Time: 24-48 hours
Result: Resulted in a slower BrdU incorporation rate of GBM cells including U251 and U343 cells.

体内研究
(In Vivo)

Parecoxib Sodium (intraperitoneal injection; 2.5, 5.0 or 10 mg/kg; once a day; 21 days) does not affect locomotor activity in the elevated plus-maze test, and Parecoxib at 5 and 10 mg/kg shows higher levels of percentage of time spent in the open arms[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Naive adult male ICR mice, 15 weeks old and weighing 25-35 g[3]
Dosage: 2.5 mg/kg, 5.0  mg/kg or 10 mg/kg
Administration: Intraperitoneal injection; 2.5, 5.0 or 10 mg/kg; once a day; 21 days
Result: Exerted an anxiolytic-like effect in the elevated plus-maze test.

Clinical Trial

分子量

392.40

Formula

C19H17N2NaO4S

CAS 号

198470-85-8

中文名称

帕瑞昔布钠

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (254.84 mM)

H2O : ≥ 100 mg/mL (254.84 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.5484 mL 12.7421 mL 25.4842 mL
5 mM 0.5097 mL 2.5484 mL 5.0968 mL
10 mM 0.2548 mL 1.2742 mL 2.5484 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (6.37 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.37 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (6.37 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.37 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (6.37 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.37 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Jun Tang, et al. Effect of parecoxib, a novel intravenous cyclooxygenase type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology

    [2]. J L Mateos, et al.[Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review]. Drugs Today (Barc). 2010 Feb;46 Suppl A:1-25.

    [3]. Bo Wang, et al. Chronic administration of parecoxib exerts anxiolytic-like and memory enhancing effects and modulates synaptophysin expression in mice. BMC Anesthesiol. 2017 Nov 13;17(1):152.

    [4]. Lin-Yong Li, et al. Parecoxib inhibits glioblastoma cell proliferation, migration and invasion by upregulating miRNA-29c. Biol Open. 2017 Mar 15;6(3):311-316.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Spectronics 11SC-1笔式紫外灯

Spectronics 11SC-1笔式紫外灯
Spectronics 11SC-1笔式紫外灯

Spectronics 11SC-1笔式紫外灯

  • 商品品牌: Spectronics
    商品编号:11SC-1
  • 商品价格: 请与我们联系
  • Spectronics 11SC-1笔式紫外灯-Spectronics-11SC-1

    • 类型:笔式
    • 波长:254nm
    • 灯管功率 :10W~40W
    • 品牌属性:进口
    生命科学仪器|||分子生物|||紫外灯|||Spectronics11SC-1笔式紫外灯
    笔式紫外灯

    美国Spectronics/斯贝克公司是美国最大的专业UV/紫外产品供应者,其UV产品超过250种,满足您的不同应用需要;超过50年的UV产品生产历史,通过ISO2000认证;Spectronics/斯贝克公司已成为紫外产品的世界领导者。

    Spectroline 11SC-1笔式紫外灯小巧轻便,特别适合于操作空间狭小的环境。

    Spectronics公司是美国最大的紫外线产品生产厂之一,生产的紫外线产品超过1000个品种,广泛应用于不同的行业。其优良的紫外线产品被获得诺贝尔奖的科学家使用进行基因基础研究。


    商品属性

    • 类型:笔式
    • 波长:254nm
    • 灯管功率 :10W~40W
    • 品牌属性:进口
    商品属性
    商品名称 Spectronics 11SC-1笔式紫外灯-11SC-1-Spectronics
    型号 11SC-1
    类别 生命科学仪器|||分子生物|||紫外灯|||Spectronics11SC-1笔式紫外灯
    品牌 Spectronics
    品牌简介 Spectronics
    关键字 笔式紫外灯,产品,贝克,美国,紫外线,波长,诺贝尔奖

    Spectronics 11SC-1笔式紫外灯 Spectronics 11SC-1笔式紫外灯

    Succinimidyl PEG NHS, mPEG-NHS(SC) Cat. No. PG1-SC-5k-1 5000 Da 1 g修饰性聚乙二醇

    上海金畔生物科技有限公司提供各种分子量和基团修饰性聚乙二醇定制服务。

    Succinimidyl PEG NHS, mPEG-NHS(SC)

    Cat. No. PG1-SC-5k-1 Succinimidyl PEG NHS, mPEG-NHS(SC)           Cat. No. PG1-SC-5k-1     5000 Da    1 g
    Specification 5000 Da
    Unit Size 1 g
    Price $295.00

    Qty Add to Cart

    Description:

    N-hydroxylsuccinimide (NHS) functionalized polyethylene glycol (PEG-NHS) is an amino (-NH2) reactive PEG derivative that can be used to modify protein, peptide or any other surfaces with their available amino groups. NHS esters react with primary amine groups at pH 7~8.5 to form stable amide bonds.Compared to other PEG NHS ester derivatives, our succinimidyl carbonate (SC) functionalized mPEG-NHS offers superior reactivity and higher stability in aqueous solution. NHS esters react with deprotonated primary amines, therefore, the reaction requires neutral to basic pH values to proceed. Primary amines react with NHS esters by nucleophilic attack and NHS is released as a byproduct. Hydrolysis of the NHS-ester competes with the reaction in aqueous solution and increases with increasing pH.

    Physical Properties:

    • Off-white/white solid or viscous liquid depends on molecule weight;
    • Soluble in regular aqeous solution as well as most organic solvents;

    Storage Conditions:

    • Store at -20 0C, desiccate. NHS PEG tends to hydrolyze from moisture. Avoid frequent thaw and frozen.

    Reaction Procedures:

    Generally, a 10 to 50-fold molar excess of NHS PEG over the amount of amine-containing material results in sufficient conjugation.

    Materials Required:

    • Conjugation buffer: Sodium bicarbonate 100 mM buffer, pH 8.5 or other amine-free buffer at pH 7-8.5.
    • PEG NHS stock solution: 100 mg in 1 mL conjugation buffer.
    • Washing solution: Distilled water or any aqueous buffer.

    Reaction Steps:

    Dissolve targeted materials in conjugation buffer. Estimate the concentration of primary amine groups on the targeted materials. Add NHS PEG stock solution to the targeted conjugation materials with the final concentration keep at least 10 mg/mL. 10~50 molar excess of PEG NHS needed for optimal conjugation; Allow mixture agitates at room temperature for 30~60 min at room temperature or 2 hours at 4 0C. Conjugates can be purified either by size exclusion chromatography or dialysis.

    Documents
    • SDS
    • DataSheet

    Succinimidyl PEG NHS, mPEG-NHS(SC) Cat. No. PG1-SC-5k-2 5000 Da 5 g修饰性聚乙二醇

    上海金畔生物科技有限公司提供各种分子量和基团修饰性聚乙二醇定制服务。

    Succinimidyl PEG NHS, mPEG-NHS(SC)

    Cat. No. PG1-SC-5k-2 Succinimidyl PEG NHS, mPEG-NHS(SC)           Cat. No. PG1-SC-5k-2     5000 Da    5 g
    Specification 5000 Da
    Unit Size 5 g
    Price $795.00

    Qty Add to Cart

    Description:

    N-hydroxylsuccinimide (NHS) functionalized polyethylene glycol (PEG-NHS) is an amino (-NH2) reactive PEG derivative that can be used to modify protein, peptide or any other surfaces with their available amino groups. NHS esters react with primary amine groups at pH 7~8.5 to form stable amide bonds.Compared to other PEG NHS ester derivatives, our succinimidyl carbonate (SC) functionalized mPEG-NHS offers superior reactivity and higher stability in aqueous solution. NHS esters react with deprotonated primary amines, therefore, the reaction requires neutral to basic pH values to proceed. Primary amines react with NHS esters by nucleophilic attack and NHS is released as a byproduct. Hydrolysis of the NHS-ester competes with the reaction in aqueous solution and increases with increasing pH.

    Physical Properties:

    • Off-white/white solid or viscous liquid depends on molecule weight;
    • Soluble in regular aqeous solution as well as most organic solvents;

    Storage Conditions:

    • Store at -20 0C, desiccate. NHS PEG tends to hydrolyze from moisture. Avoid frequent thaw and frozen.

    Reaction Procedures:

    Generally, a 10 to 50-fold molar excess of NHS PEG over the amount of amine-containing material results in sufficient conjugation.

    Materials Required:

    • Conjugation buffer: Sodium bicarbonate 100 mM buffer, pH 8.5 or other amine-free buffer at pH 7-8.5.
    • PEG NHS stock solution: 100 mg in 1 mL conjugation buffer.
    • Washing solution: Distilled water or any aqueous buffer.

    Reaction Steps:

    Dissolve targeted materials in conjugation buffer. Estimate the concentration of primary amine groups on the targeted materials. Add NHS PEG stock solution to the targeted conjugation materials with the final concentration keep at least 10 mg/mL. 10~50 molar excess of PEG NHS needed for optimal conjugation; Allow mixture agitates at room temperature for 30~60 min at room temperature or 2 hours at 4 0C. Conjugates can be purified either by size exclusion chromatography or dialysis.

    Documents
    • SDS
    • DataSheet

    Succinimidyl PEG NHS, mPEG-NHS(SC) Cat. No. PG1-SC-2k-1 2000 Da 1 g修饰性聚乙二醇

    上海金畔生物科技有限公司提供各种分子量和基团修饰性聚乙二醇定制服务。

    Succinimidyl PEG NHS, mPEG-NHS(SC)

    Cat. No. PG1-SC-2k-1 Succinimidyl PEG NHS, mPEG-NHS(SC)           Cat. No. PG1-SC-2k-1     2000 Da    1 g
    Specification 2000 Da
    Unit Size 1 g
    Price $325.00

    Qty Add to Cart

    Description:

    N-hydroxylsuccinimide (NHS) functionalized polyethylene glycol (PEG-NHS) is an amino (-NH2) reactive PEG derivative that can be used to modify protein, peptide or any other surfaces with their available amino groups. NHS esters react with primary amine groups at pH 7~8.5 to form stable amide bonds.Compared to other PEG NHS ester derivatives, our succinimidyl carbonate (SC) functionalized mPEG-NHS offers superior reactivity and higher stability in aqueous solution. NHS esters react with deprotonated primary amines, therefore, the reaction requires neutral to basic pH values to proceed. Primary amines react with NHS esters by nucleophilic attack and NHS is released as a byproduct. Hydrolysis of the NHS-ester competes with the reaction in aqueous solution and increases with increasing pH.

    Physical Properties:

    • Off-white/white solid or viscous liquid depends on molecule weight;
    • Soluble in regular aqeous solution as well as most organic solvents;

    Storage Conditions:

    • Store at -20 0C, desiccate. NHS PEG tends to hydrolyze from moisture. Avoid frequent thaw and frozen.

    Reaction Procedures:

    Generally, a 10 to 50-fold molar excess of NHS PEG over the amount of amine-containing material results in sufficient conjugation.

    Materials Required:

    • Conjugation buffer: Sodium bicarbonate 100 mM buffer, pH 8.5 or other amine-free buffer at pH 7-8.5.
    • PEG NHS stock solution: 100 mg in 1 mL conjugation buffer.
    • Washing solution: Distilled water or any aqueous buffer.

    Reaction Steps:

    Dissolve targeted materials in conjugation buffer. Estimate the concentration of primary amine groups on the targeted materials. Add NHS PEG stock solution to the targeted conjugation materials with the final concentration keep at least 10 mg/mL. 10~50 molar excess of PEG NHS needed for optimal conjugation; Allow mixture agitates at room temperature for 30~60 min at room temperature or 2 hours at 4 0C. Conjugates can be purified either by size exclusion chromatography or dialysis.

    Documents
    • SDS
    • DataSheet

    Succinimidyl PEG NHS, mPEG-NHS(SC) Cat. No. PG1-SC-2k-2 2000 Da 5 g修饰性聚乙二醇

    上海金畔生物科技有限公司提供各种分子量和基团修饰性聚乙二醇定制服务。

    Succinimidyl PEG NHS, mPEG-NHS(SC)

    Cat. No. PG1-SC-2k-2 Succinimidyl PEG NHS, mPEG-NHS(SC)           Cat. No. PG1-SC-2k-2     2000 Da    5 g
    Specification 2000 Da
    Unit Size 5 g
    Price $845.00

    Qty Add to Cart

    Description:

    N-hydroxylsuccinimide (NHS) functionalized polyethylene glycol (PEG-NHS) is an amino (-NH2) reactive PEG derivative that can be used to modify protein, peptide or any other surfaces with their available amino groups. NHS esters react with primary amine groups at pH 7~8.5 to form stable amide bonds.Compared to other PEG NHS ester derivatives, our succinimidyl carbonate (SC) functionalized mPEG-NHS offers superior reactivity and higher stability in aqueous solution. NHS esters react with deprotonated primary amines, therefore, the reaction requires neutral to basic pH values to proceed. Primary amines react with NHS esters by nucleophilic attack and NHS is released as a byproduct. Hydrolysis of the NHS-ester competes with the reaction in aqueous solution and increases with increasing pH.

    Physical Properties:

    • Off-white/white solid or viscous liquid depends on molecule weight;
    • Soluble in regular aqeous solution as well as most organic solvents;

    Storage Conditions:

    • Store at -20 0C, desiccate. NHS PEG tends to hydrolyze from moisture. Avoid frequent thaw and frozen.

    Reaction Procedures:

    Generally, a 10 to 50-fold molar excess of NHS PEG over the amount of amine-containing material results in sufficient conjugation.

    Materials Required:

    • Conjugation buffer: Sodium bicarbonate 100 mM buffer, pH 8.5 or other amine-free buffer at pH 7-8.5.
    • PEG NHS stock solution: 100 mg in 1 mL conjugation buffer.
    • Washing solution: Distilled water or any aqueous buffer.

    Reaction Steps:

    Dissolve targeted materials in conjugation buffer. Estimate the concentration of primary amine groups on the targeted materials. Add NHS PEG stock solution to the targeted conjugation materials with the final concentration keep at least 10 mg/mL. 10~50 molar excess of PEG NHS needed for optimal conjugation; Allow mixture agitates at room temperature for 30~60 min at room temperature or 2 hours at 4 0C. Conjugates can be purified either by size exclusion chromatography or dialysis.

    Documents
    • SDS
    • DataSheet

    Succinimidyl PEG NHS, mPEG-NHS(SC) Cat. No. PG1-SC-1k-1 1000 Da 1 g修饰性聚乙二醇

    上海金畔生物科技有限公司提供各种分子量和基团修饰性聚乙二醇定制服务。

    Succinimidyl PEG NHS, mPEG-NHS(SC)

    Cat. No. PG1-SC-1k-1 Succinimidyl PEG NHS, mPEG-NHS(SC)           Cat. No. PG1-SC-1k-1     1000 Da    1 g
    Specification 1000 Da
    Unit Size 1 g
    Price $385.00

    Qty Add to Cart

    Description:

    N-hydroxylsuccinimide (NHS) functionalized polyethylene glycol (PEG-NHS) is an amino (-NH2) reactive PEG derivative that can be used to modify protein, peptide or any other surfaces with their available amino groups. NHS esters react with primary amine groups at pH 7~8.5 to form stable amide bonds.Compared to other PEG NHS ester derivatives, our succinimidyl carbonate (SC) functionalized mPEG-NHS offers superior reactivity and higher stability in aqueous solution. NHS esters react with deprotonated primary amines, therefore, the reaction requires neutral to basic pH values to proceed. Primary amines react with NHS esters by nucleophilic attack and NHS is released as a byproduct. Hydrolysis of the NHS-ester competes with the reaction in aqueous solution and increases with increasing pH.

    Physical Properties:

    • Off-white/white solid or viscous liquid depends on molecule weight;
    • Soluble in regular aqeous solution as well as most organic solvents;

    Storage Conditions:

    • Store at -20 0C, desiccate. NHS PEG tends to hydrolyze from moisture. Avoid frequent thaw and frozen.

    Reaction Procedures:

    Generally, a 10 to 50-fold molar excess of NHS PEG over the amount of amine-containing material results in sufficient conjugation.

    Materials Required:

    • Conjugation buffer: Sodium bicarbonate 100 mM buffer, pH 8.5 or other amine-free buffer at pH 7-8.5.
    • PEG NHS stock solution: 100 mg in 1 mL conjugation buffer.
    • Washing solution: Distilled water or any aqueous buffer.

    Reaction Steps:

    Dissolve targeted materials in conjugation buffer. Estimate the concentration of primary amine groups on the targeted materials. Add NHS PEG stock solution to the targeted conjugation materials with the final concentration keep at least 10 mg/mL. 10~50 molar excess of PEG NHS needed for optimal conjugation; Allow mixture agitates at room temperature for 30~60 min at room temperature or 2 hours at 4 0C. Conjugates can be purified either by size exclusion chromatography or dialysis.

    Documents
    • SDS
    • DataSheet

    Succinimidyl PEG NHS, mPEG-NHS(SC) Cat. No. PG1-SC-1k-2 1000 Da 5 g修饰性聚乙二醇

    上海金畔生物科技有限公司提供各种分子量和基团修饰性聚乙二醇定制服务。

    Succinimidyl PEG NHS, mPEG-NHS(SC)

    Cat. No. PG1-SC-1k-2 Succinimidyl PEG NHS, mPEG-NHS(SC)           Cat. No. PG1-SC-1k-2     1000 Da    5 g
    Specification 1000 Da
    Unit Size 5 g
    Price $980.00

    Qty Add to Cart

    Description:

    N-hydroxylsuccinimide (NHS) functionalized polyethylene glycol (PEG-NHS) is an amino (-NH2) reactive PEG derivative that can be used to modify protein, peptide or any other surfaces with their available amino groups. NHS esters react with primary amine groups at pH 7~8.5 to form stable amide bonds.Compared to other PEG NHS ester derivatives, our succinimidyl carbonate (SC) functionalized mPEG-NHS offers superior reactivity and higher stability in aqueous solution. NHS esters react with deprotonated primary amines, therefore, the reaction requires neutral to basic pH values to proceed. Primary amines react with NHS esters by nucleophilic attack and NHS is released as a byproduct. Hydrolysis of the NHS-ester competes with the reaction in aqueous solution and increases with increasing pH.

    Physical Properties:

    • Off-white/white solid or viscous liquid depends on molecule weight;
    • Soluble in regular aqeous solution as well as most organic solvents;

    Storage Conditions:

    • Store at -20 0C, desiccate. NHS PEG tends to hydrolyze from moisture. Avoid frequent thaw and frozen.

    Reaction Procedures:

    Generally, a 10 to 50-fold molar excess of NHS PEG over the amount of amine-containing material results in sufficient conjugation.

    Materials Required:

    • Conjugation buffer: Sodium bicarbonate 100 mM buffer, pH 8.5 or other amine-free buffer at pH 7-8.5.
    • PEG NHS stock solution: 100 mg in 1 mL conjugation buffer.
    • Washing solution: Distilled water or any aqueous buffer.

    Reaction Steps:

    Dissolve targeted materials in conjugation buffer. Estimate the concentration of primary amine groups on the targeted materials. Add NHS PEG stock solution to the targeted conjugation materials with the final concentration keep at least 10 mg/mL. 10~50 molar excess of PEG NHS needed for optimal conjugation; Allow mixture agitates at room temperature for 30~60 min at room temperature or 2 hours at 4 0C. Conjugates can be purified either by size exclusion chromatography or dialysis.

    Documents
    • SDS
    • DataSheet

    Succinimidyl PEG NHS, mPEG-NHS(SC) Cat. No. PG1-SC-10k 10000 Da 500 mg修饰性聚乙二醇

    上海金畔生物科技有限公司提供各种分子量和基团修饰性聚乙二醇定制服务。

    Succinimidyl PEG NHS, mPEG-NHS(SC)

    Cat. No. PG1-SC-10k Succinimidyl PEG NHS, mPEG-NHS(SC)           Cat. No. PG1-SC-10k     10000 Da    500 mg
    Specification 10000 Da
    Unit Size 500 mg
    Price $385.00

    Qty Add to Cart

    Description:

    N-hydroxylsuccinimide (NHS) functionalized polyethylene glycol (PEG-NHS) is an amino (-NH2) reactive PEG derivative that can be used to modify protein, peptide or any other surfaces with their available amino groups. NHS esters react with primary amine groups at pH 7~8.5 to form stable amide bonds.Compared to other PEG NHS ester derivatives, our succinimidyl carbonate (SC) functionalized mPEG-NHS offers superior reactivity and higher stability in aqueous solution. NHS esters react with deprotonated primary amines, therefore, the reaction requires neutral to basic pH values to proceed. Primary amines react with NHS esters by nucleophilic attack and NHS is released as a byproduct. Hydrolysis of the NHS-ester competes with the reaction in aqueous solution and increases with increasing pH.

    Physical Properties:

    • Off-white/white solid or viscous liquid depends on molecule weight;
    • Soluble in regular aqeous solution as well as most organic solvents;

    Storage Conditions:

    • Store at -20 0C, desiccate. NHS PEG tends to hydrolyze from moisture. Avoid frequent thaw and frozen.

    Reaction Procedures:

    Generally, a 10 to 50-fold molar excess of NHS PEG over the amount of amine-containing material results in sufficient conjugation.

    Materials Required:

    • Conjugation buffer: Sodium bicarbonate 100 mM buffer, pH 8.5 or other amine-free buffer at pH 7-8.5.
    • PEG NHS stock solution: 100 mg in 1 mL conjugation buffer.
    • Washing solution: Distilled water or any aqueous buffer.

    Reaction Steps:

    Dissolve targeted materials in conjugation buffer. Estimate the concentration of primary amine groups on the targeted materials. Add NHS PEG stock solution to the targeted conjugation materials with the final concentration keep at least 10 mg/mL. 10~50 molar excess of PEG NHS needed for optimal conjugation; Allow mixture agitates at room temperature for 30~60 min at room temperature or 2 hours at 4 0C. Conjugates can be purified either by size exclusion chromatography or dialysis.

    Documents
    • SDS
    • DataSheet

    Succinimidyl PEG NHS, mPEG-NHS(SC) Cat. No. PG1-SC-12k 12000 Da 500 mg修饰性聚乙二醇

    上海金畔生物科技有限公司提供各种分子量和基团修饰性聚乙二醇定制服务。

    Succinimidyl PEG NHS, mPEG-NHS(SC)

    Cat. No. PG1-SC-12k Succinimidyl PEG NHS, mPEG-NHS(SC)           Cat. No. PG1-SC-12k     12000 Da    500 mg
    Specification 12000 Da
    Unit Size 500 mg
    Price $385.00

    Qty Add to Cart

    Description:

    N-hydroxylsuccinimide (NHS) functionalized polyethylene glycol (PEG-NHS) is an amino (-NH2) reactive PEG derivative that can be used to modify protein, peptide or any other surfaces with their available amino groups. NHS esters react with primary amine groups at pH 7~8.5 to form stable amide bonds.Compared to other PEG NHS ester derivatives, our succinimidyl carbonate (SC) functionalized mPEG-NHS offers superior reactivity and higher stability in aqueous solution. NHS esters react with deprotonated primary amines, therefore, the reaction requires neutral to basic pH values to proceed. Primary amines react with NHS esters by nucleophilic attack and NHS is released as a byproduct. Hydrolysis of the NHS-ester competes with the reaction in aqueous solution and increases with increasing pH.

    Physical Properties:

    • Off-white/white solid or viscous liquid depends on molecule weight;
    • Soluble in regular aqeous solution as well as most organic solvents;

    Storage Conditions:

    • Store at -20 0C, desiccate. NHS PEG tends to hydrolyze from moisture. Avoid frequent thaw and frozen.

    Reaction Procedures:

    Generally, a 10 to 50-fold molar excess of NHS PEG over the amount of amine-containing material results in sufficient conjugation.

    Materials Required:

    • Conjugation buffer: Sodium bicarbonate 100 mM buffer, pH 8.5 or other amine-free buffer at pH 7-8.5.
    • PEG NHS stock solution: 100 mg in 1 mL conjugation buffer.
    • Washing solution: Distilled water or any aqueous buffer.

    Reaction Steps:

    Dissolve targeted materials in conjugation buffer. Estimate the concentration of primary amine groups on the targeted materials. Add NHS PEG stock solution to the targeted conjugation materials with the final concentration keep at least 10 mg/mL. 10~50 molar excess of PEG NHS needed for optimal conjugation; Allow mixture agitates at room temperature for 30~60 min at room temperature or 2 hours at 4 0C. Conjugates can be purified either by size exclusion chromatography or dialysis.

    Documents
    • SDS
    • DataSheet

    Succinimidyl PEG NHS, mPEG-NHS(SC) Cat. No. PG1-SC-20k 20000 Da 500 mg修饰性聚乙二醇

    上海金畔生物科技有限公司提供各种分子量和基团修饰性聚乙二醇定制服务。

    Succinimidyl PEG NHS, mPEG-NHS(SC)

    Cat. No. PG1-SC-20k Succinimidyl PEG NHS, mPEG-NHS(SC)           Cat. No. PG1-SC-20k     20000 Da    500 mg
    Specification 20000 Da
    Unit Size 500 mg
    Price $385.00

    Qty Add to Cart

    Description:

    N-hydroxylsuccinimide (NHS) functionalized polyethylene glycol (PEG-NHS) is an amino (-NH2) reactive PEG derivative that can be used to modify protein, peptide or any other surfaces with their available amino groups. NHS esters react with primary amine groups at pH 7~8.5 to form stable amide bonds.Compared to other PEG NHS ester derivatives, our succinimidyl carbonate (SC) functionalized mPEG-NHS offers superior reactivity and higher stability in aqueous solution. NHS esters react with deprotonated primary amines, therefore, the reaction requires neutral to basic pH values to proceed. Primary amines react with NHS esters by nucleophilic attack and NHS is released as a byproduct. Hydrolysis of the NHS-ester competes with the reaction in aqueous solution and increases with increasing pH.

    Physical Properties:

    • Off-white/white solid or viscous liquid depends on molecule weight;
    • Soluble in regular aqeous solution as well as most organic solvents;

    Storage Conditions:

    • Store at -20 0C, desiccate. NHS PEG tends to hydrolyze from moisture. Avoid frequent thaw and frozen.

    Reaction Procedures:

    Generally, a 10 to 50-fold molar excess of NHS PEG over the amount of amine-containing material results in sufficient conjugation.

    Materials Required:

    • Conjugation buffer: Sodium bicarbonate 100 mM buffer, pH 8.5 or other amine-free buffer at pH 7-8.5.
    • PEG NHS stock solution: 100 mg in 1 mL conjugation buffer.
    • Washing solution: Distilled water or any aqueous buffer.

    Reaction Steps:

    Dissolve targeted materials in conjugation buffer. Estimate the concentration of primary amine groups on the targeted materials. Add NHS PEG stock solution to the targeted conjugation materials with the final concentration keep at least 10 mg/mL. 10~50 molar excess of PEG NHS needed for optimal conjugation; Allow mixture agitates at room temperature for 30~60 min at room temperature or 2 hours at 4 0C. Conjugates can be purified either by size exclusion chromatography or dialysis.

    Documents
    • SDS
    • DataSheet

    Succinimidyl PEG NHS, mPEG-NHS(SC) Cat. No. PG1-SC-30k 30000 Da 500 mg修饰性聚乙二醇

    上海金畔生物科技有限公司提供各种分子量和基团修饰性聚乙二醇定制服务。

    Succinimidyl PEG NHS, mPEG-NHS(SC)

    Cat. No. PG1-SC-30k Succinimidyl PEG NHS, mPEG-NHS(SC)           Cat. No. PG1-SC-30k     30000 Da    500 mg
    Specification 30000 Da
    Unit Size 500 mg
    Price $425.00

    Qty Add to Cart

    Description:

    N-hydroxylsuccinimide (NHS) functionalized polyethylene glycol (PEG-NHS) is an amino (-NH2) reactive PEG derivative that can be used to modify protein, peptide or any other surfaces with their available amino groups. NHS esters react with primary amine groups at pH 7~8.5 to form stable amide bonds.Compared to other PEG NHS ester derivatives, our succinimidyl carbonate (SC) functionalized mPEG-NHS offers superior reactivity and higher stability in aqueous solution. NHS esters react with deprotonated primary amines, therefore, the reaction requires neutral to basic pH values to proceed. Primary amines react with NHS esters by nucleophilic attack and NHS is released as a byproduct. Hydrolysis of the NHS-ester competes with the reaction in aqueous solution and increases with increasing pH.

    Physical Properties:

    • Off-white/white solid or viscous liquid depends on molecule weight;
    • Soluble in regular aqeous solution as well as most organic solvents;

    Storage Conditions:

    • Store at -20 0C, desiccate. NHS PEG tends to hydrolyze from moisture. Avoid frequent thaw and frozen.

    Reaction Procedures:

    Generally, a 10 to 50-fold molar excess of NHS PEG over the amount of amine-containing material results in sufficient conjugation.

    Materials Required:

    • Conjugation buffer: Sodium bicarbonate 100 mM buffer, pH 8.5 or other amine-free buffer at pH 7-8.5.
    • PEG NHS stock solution: 100 mg in 1 mL conjugation buffer.
    • Washing solution: Distilled water or any aqueous buffer.

    Reaction Steps:

    Dissolve targeted materials in conjugation buffer. Estimate the concentration of primary amine groups on the targeted materials. Add NHS PEG stock solution to the targeted conjugation materials with the final concentration keep at least 10 mg/mL. 10~50 molar excess of PEG NHS needed for optimal conjugation; Allow mixture agitates at room temperature for 30~60 min at room temperature or 2 hours at 4 0C. Conjugates can be purified either by size exclusion chromatography or dialysis.

    Documents
    • SDS
    • DataSheet

    Succinimidyl PEG NHS, mPEG-NHS(SC) Cat. No. PG1-SC-40k 40000 Da 500 mg修饰性聚乙二醇

    上海金畔生物科技有限公司提供各种分子量和基团修饰性聚乙二醇定制服务。

    Succinimidyl PEG NHS, mPEG-NHS(SC)

    Cat. No. PG1-SC-40k Succinimidyl PEG NHS, mPEG-NHS(SC)           Cat. No. PG1-SC-40k     40000 Da    500 mg
    Specification 40000 Da
    Unit Size 500 mg
    Price $485.00

    Qty Add to Cart

    Description:

    N-hydroxylsuccinimide (NHS) functionalized polyethylene glycol (PEG-NHS) is an amino (-NH2) reactive PEG derivative that can be used to modify protein, peptide or any other surfaces with their available amino groups. NHS esters react with primary amine groups at pH 7~8.5 to form stable amide bonds.Compared to other PEG NHS ester derivatives, our succinimidyl carbonate (SC) functionalized mPEG-NHS offers superior reactivity and higher stability in aqueous solution. NHS esters react with deprotonated primary amines, therefore, the reaction requires neutral to basic pH values to proceed. Primary amines react with NHS esters by nucleophilic attack and NHS is released as a byproduct. Hydrolysis of the NHS-ester competes with the reaction in aqueous solution and increases with increasing pH.

    Physical Properties:

    • Off-white/white solid or viscous liquid depends on molecule weight;
    • Soluble in regular aqeous solution as well as most organic solvents;

    Storage Conditions:

    • Store at -20 0C, desiccate. NHS PEG tends to hydrolyze from moisture. Avoid frequent thaw and frozen.

    Reaction Procedures:

    Generally, a 10 to 50-fold molar excess of NHS PEG over the amount of amine-containing material results in sufficient conjugation.

    Materials Required:

    • Conjugation buffer: Sodium bicarbonate 100 mM buffer, pH 8.5 or other amine-free buffer at pH 7-8.5.
    • PEG NHS stock solution: 100 mg in 1 mL conjugation buffer.
    • Washing solution: Distilled water or any aqueous buffer.

    Reaction Steps:

    Dissolve targeted materials in conjugation buffer. Estimate the concentration of primary amine groups on the targeted materials. Add NHS PEG stock solution to the targeted conjugation materials with the final concentration keep at least 10 mg/mL. 10~50 molar excess of PEG NHS needed for optimal conjugation; Allow mixture agitates at room temperature for 30~60 min at room temperature or 2 hours at 4 0C. Conjugates can be purified either by size exclusion chromatography or dialysis.

    Documents
    • SDS
    • DataSheet

    SC-58125

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

    SC-58125 

    SC-58125 是一种有效的和选择性的环氧合酶 2 (COX-2) 的抑制剂,IC50 值为 0.04 μM。SC-58125 在体外和体内均表现出抗肿瘤活性,还可以抑制炎症部位的水肿并具有缓解疼痛作用。

    SC-58125

    SC-58125 Chemical Structure

    CAS No. : 162054-19-5

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    SC-58125 is a potent and selective inhibitor of cyclooxygenase 2 (COX-2), with an IC50 of 0.04 μM. SC-58125 exhibits antitumor activity in vitro and in vivo. SC-58125 also can inhibit edema at the inflammatory site and has analgesic effect[1][2][3].

    IC50 & Target

    hCOX-2

    0.04 μM (IC50)

    hCOX-1

    >100 μM (IC50)

    体外研究
    (In Vitro)

    SC-58125 (0.001-100 μM) has a high degree of selectivity for the inducible form of COX-2 (IC50=1 μM) over the COX-1 (IC50>100 μM)[1].
    SC-58125 (10 μM; 20-140 s) is time-dependent and is complete by 1 min, with a half-maximal inhibition at 20 s[1].
    SC-58125 (25-100 μM; 3 d) inhibits the in vitro growth of HCA-7 and LLC cells[3].
    SC-58125 (100 µM; 12 h) induces G2 arrest in LLC cells[3].
    SC-58125 (25-100 μM; 3 d) decreases p34cdc2 levels in HCA-7 cells[3].
    SC-58125 (100 µM; 24 or 72 h) does not induce apoptosis of HCA-7 and LLC cells[3].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Proliferation Assay[3]

    Cell Line: HCA-7 and LLC cells
    Concentration: 0, 25, 50, 100 μM
    Incubation Time: 3 days
    Result: Reduced the cell number and MTT activity in both cell lines in a dose-dependent manner.

    Cell Cycle Analysis[3]

    Cell Line: LLC cells
    Concentration: 100 μM
    Incubation Time: 12 hours
    Result: Increased in the number of cells containing 4n DNA content in a dose- and time-dependent manner.
    Reduced the number of mitotic figures.

    Western Blot Analysis[3]

    Cell Line: HCA-7 cells
    Concentration: 0, 25, 50, 100 μM
    Incubation Time: 3 days
    Result: Resulted in a dose-dependent decrease in p34cdc2 activity with strong inhibition, even at the lowest concentration.

    体内研究
    (In Vivo)

    SC-58125 (10 mg/kg; i.p. every 48 h) inhibits the growth of established colorectal cancer xenografts in mice[3].
    SC-58125 (10 mg/kg; a single i.p.) reduces tumor PGE2 levels in mice[3].
    SC-58125 (10 mg/kg; a single i.p.) does not change the tumor levels of COX-1 and COX-2 protein in mice[3].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Athymic Sprague-Dawley mice are injected HCA-7 cells[3]
    Dosage: 10 mg/kg
    Administration: I.p. every 48 h; at the time of tumor implantation or 2 and 4 weeks later
    Result: Decreased the tumor growth rates significantly.

    分子量

    384.35

    Formula

    C17H12F4N2O2S

    CAS 号

    162054-19-5

    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.

    参考文献
    • [1]. Gierse JK, et, al. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem. 1996 Jun 28; 271(26): 15810-4.

      [2]. Seibert K, et, al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A. 1994 Dec 6; 91(25): 12013-7.

      [3]. Williams CS, et, al. A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. Neoplasia. Sep-Oct 2001; 3(5): 428-36.

    所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

    SC-58125

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

    SC-58125 

    SC-58125 是一种有效的和选择性的环氧合酶 2 (COX-2) 的抑制剂,IC50 值为 0.04 μM。SC-58125 在体外和体内均表现出抗肿瘤活性,还可以抑制炎症部位的水肿并具有缓解疼痛作用。

    SC-58125

    SC-58125 Chemical Structure

    CAS No. : 162054-19-5

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    SC-58125 is a potent and selective inhibitor of cyclooxygenase 2 (COX-2), with an IC50 of 0.04 μM. SC-58125 exhibits antitumor activity in vitro and in vivo. SC-58125 also can inhibit edema at the inflammatory site and has analgesic effect[1][2][3].

    IC50 & Target

    hCOX-2

    0.04 μM (IC50)

    hCOX-1

    >100 μM (IC50)

    体外研究
    (In Vitro)

    SC-58125 (0.001-100 μM) has a high degree of selectivity for the inducible form of COX-2 (IC50=1 μM) over the COX-1 (IC50>100 μM)[1].
    SC-58125 (10 μM; 20-140 s) is time-dependent and is complete by 1 min, with a half-maximal inhibition at 20 s[1].
    SC-58125 (25-100 μM; 3 d) inhibits the in vitro growth of HCA-7 and LLC cells[3].
    SC-58125 (100 µM; 12 h) induces G2 arrest in LLC cells[3].
    SC-58125 (25-100 μM; 3 d) decreases p34cdc2 levels in HCA-7 cells[3].
    SC-58125 (100 µM; 24 or 72 h) does not induce apoptosis of HCA-7 and LLC cells[3].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Proliferation Assay[3]

    Cell Line: HCA-7 and LLC cells
    Concentration: 0, 25, 50, 100 μM
    Incubation Time: 3 days
    Result: Reduced the cell number and MTT activity in both cell lines in a dose-dependent manner.

    Cell Cycle Analysis[3]

    Cell Line: LLC cells
    Concentration: 100 μM
    Incubation Time: 12 hours
    Result: Increased in the number of cells containing 4n DNA content in a dose- and time-dependent manner.
    Reduced the number of mitotic figures.

    Western Blot Analysis[3]

    Cell Line: HCA-7 cells
    Concentration: 0, 25, 50, 100 μM
    Incubation Time: 3 days
    Result: Resulted in a dose-dependent decrease in p34cdc2 activity with strong inhibition, even at the lowest concentration.

    体内研究
    (In Vivo)

    SC-58125 (10 mg/kg; i.p. every 48 h) inhibits the growth of established colorectal cancer xenografts in mice[3].
    SC-58125 (10 mg/kg; a single i.p.) reduces tumor PGE2 levels in mice[3].
    SC-58125 (10 mg/kg; a single i.p.) does not change the tumor levels of COX-1 and COX-2 protein in mice[3].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Athymic Sprague-Dawley mice are injected HCA-7 cells[3]
    Dosage: 10 mg/kg
    Administration: I.p. every 48 h; at the time of tumor implantation or 2 and 4 weeks later
    Result: Decreased the tumor growth rates significantly.

    分子量

    384.35

    Formula

    C17H12F4N2O2S

    CAS 号

    162054-19-5

    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.

    参考文献
    • [1]. Gierse JK, et, al. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem. 1996 Jun 28; 271(26): 15810-4.

      [2]. Seibert K, et, al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A. 1994 Dec 6; 91(25): 12013-7.

      [3]. Williams CS, et, al. A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. Neoplasia. Sep-Oct 2001; 3(5): 428-36.

    所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务